News for Arrowhead Research Corporation - Google FinanceNews for Arrowhead Research Corporation - Google FinanceCalando Pharmaceuticals Announces Next SiRNA Therapeutic Candidate For Oncology - CALAA-02, Targeting HIF-2alpha- September 17, 2008 Calando Pharmaceuticals Announces Next SiRNA Therapeutic Candidate For Oncology - CALAA-02, Targeting HIF-2alpha Medical News Today (press release) - 12 hours ago Calando Pharmaceuticals , a majority - owned subsidiary of Arrowhead Research Corporation ( NASDAQ : ARWR ) , announced that pre - clinical development of a second siRNA oncology therapeutic ...http://www.medicalnewstoday.com/articles/121734.php Calando Pharmaceuticals announces development of a second siRNA oncology therapeutic, CALAA-02, targeting HIF-2alpha- September 15, 2008 Calando Pharmaceuticals announces development of a second siRNA oncology therapeutic, CALAA-02, targeting HIF-2alpha PipelineReview.com (press release) - Sep 15, 2008 PASADENA , CA , USA September 15 , 2008 Calando Pharmaceuticals , a majority - owned subsidiary of Arrowhead Research Corporation ( NASDAQ : ARWR ) , announced today that pre - clinical development ...http://www.pipelinereview.com/content/view/22075/104/ NMSU: First Arrowhead building set for February completion- September 15, 2008 NMSU: First Arrowhead building set for February completion Las Cruces Sun-News - Sep 15, 2008 LAS CRUCES - A little more than a year has passed since New Mexico State University broke ground for its Arrowhead Research Park.Situated just off Sam Steel Way , between Interstates 10 and 25 ...http://www.lcsun-news.com/ci_10470702 Calando Pharmaceuticals announces development of a second siRNA oncology therapeutic, CALAA-02, targeting HIF-2alpha- September 15, 2008 Calando Pharmaceuticals announces development of a second siRNA oncology therapeutic, CALAA-02, targeting HIF-2alpha Business Wire (press release) - Sep 15, 2008 PASADENA , Calif . - - ( BUSINESS WIRE ) - - Calando Pharmaceuticals , a majority - owned subsidiary of Arrowhead Research Corporation ( NASDAQ : ARWR ) , announced today that pre - clinical ...http://www.businesswire.com/news/google/20080915005672/en Calando Pharmaceuticals Phase II Clinical Study Opens to Patient Enrollment- September 11, 2008 Calando Pharmaceuticals Phase II Clinical Study Opens to Patient Enrollment Business Wire (press release) - Sep 11, 2008 PASADENA , Calif . - - ( BUSINESS WIRE ) - - Calando Pharmaceuticals , Inc . , a majority owned subsidiary of Arrowhead Research Corporation ( NASDAQ : ARWR ) , announced today that it has initiated ...http://www.businesswire.com/news/google/20080911005303/en Arrowhead Research initiates Phase II clinical trial of IT-101 - Quick Facts- September 11, 2008 Arrowhead Research initiates Phase II clinical trial of IT-101 - Quick Facts RTT News - Sep 11, 2008 ( RTTNews ) - Arrowhead Research Corp . ( ARWR : News ) announced that it has commenced a Phase II clinical trial in the United States evaluating the safety and efficacy of IT - 101 in patients ...http://www.rttnews.com/Content/QuickFacts.aspx?Node=B1&Id=707821%20&Category=Quick... Arrowhead Completes Previously Announced Registered Direct Offering- September 9, 2008 Arrowhead Completes Previously Announced Registered Direct Offering Business Wire (press release) - Sep 9, 2008 PASADENA , Calif . - - ( BUSINESS WIRE ) - - Arrowhead Research Corporation ( NASDAQ : ARWR ) announced today that it has completed its previously announced registered direct offering , increasing ...http://www.businesswire.com/news/google/20080909005656/en Scripps Florida, cuRNA, Miragen, Arrowhead Research- September 4, 2008 Scripps Florida, cuRNA, Miragen, Arrowhead Research RNAi News (subscription) - Sep 4, 2008 Scripps Florida Professor Claes Wahlstedt has founded a new firm , called cuRNA , that will develop therapeutics and possibly diagnostic biomarkers based on non - coding RNA technology licensed ...http://www.rnainews.com/issues/6_35/strands/149192-1.html |